ライフサイエンスコーパス: oxytocin

1 , dynorphin, corticotropin-releasing factor, oxytocin).

2 nedioxymethamphetamine (MDMA) and intranasal oxytocin.

3 eptide, angiotensin II, and the nonapeptide, oxytocin.

4 y oxytocin is a weak surrogate for plasmatic oxytocin.

5 ght amygdala activation after 8IU intranasal oxytocin.

6 e and do not express arginine vasopressin or oxytocin.

7 nd mirror neurons; and it is associated with oxytocin.

8 The effects of oxytocin (0.03-0.3 mg/kg subcutaneous) on locomotor acti

9 In the same rats, oxytocin (0.1 mg/kg) selectively elevated dopamine overf

10 s, were administered MDMA (0.75, 1.5 mg/kg), oxytocin (20 IU), and placebo in randomized, double-blin

11 another secondary endpoint, was increased by oxytocin (41.2 to 52.3; P = .03) compared with placebo (

12 ls of repeated intranasal administrations of oxytocin (48 IU/day) in adult males with autism spectrum

13 ere randomly assigned to a 6-week intranasal oxytocin (48IU/day, n = 53) or placebo (n = 53) group.

14 rrent study investigated the hypothesis that oxytocin, a neuropeptide implicated in social behavior,

15 tation of social value and the modulation by oxytocin, a nine-amino acid neuropeptide, in participant

16 c brain regions, such as the striatum, where oxytocin acts to impact motivated behaviors.

17 Intranasal oxytocin administration amplified this amygdala represen

18 Both intranasal oxytocin administration and chemogenetic stimulation of

19 Systemic oxytocin administration attenuated phencyclidine-induced

20 Intraperitoneal oxytocin administration blocked escalated alcohol drinki

21 olic palatable solutions, whereas intranasal oxytocin administration did not.

22 Oxytocin administration has been reported to decrease co

23 frontopolar cortex) brain regions following oxytocin administration vs placebo.

24 nt experienced temporary gynecomastia during oxytocin administration.

25 oxytocin in 12 brain regions two hours after oxytocin administration.

26 tested the effects of OC on plasma levels of oxytocin, adrenocorticotropic hormone (ACTH), estradiol,

27 ecordings in slices and RNAscope showed that oxytocin affects S1 excitatory and inhibitory neurons si

28 The present work suggests that oxytocin also modulates pain at the cortical insular lev

29 Oxytocin also significantly improved connectivity betwee

30 s selective to common interferences, such as oxytocin analogs and potential metabolites.

31 vEDS patients, was rescued by attenuation of oxytocin and androgen signaling, respectively.

32 ignificant difference between 8IU intranasal oxytocin and either 24IU intranasal oxytocin or IV oxyto

33 n modulating nociception could exist between oxytocin and GABA at RAIC.

34 cotropin releasing hormone and its receptor, oxytocin and its receptor, estrogen receptor beta, serot

35 ignificant difference between 8IU intranasal oxytocin and IV oxytocin on right amygdala activity and

36 The two hypothalamic neuropeptides oxytocin and melanin concentrating hormone (MCH) share s

37 g on 2 occasions, once after 40IU intranasal oxytocin and once after placebo.

38 ignificant difference between 8IU intranasal oxytocin and placebo is consistent with the hypothesis t

39 controlled by brain neuromodulators, such as oxytocin and serotonin.

40 served, whereas approximately 20% and 38% of oxytocin and tyrosine hydroxylase (TH) cells, respective

41 of evidence has implicated the neuropeptides oxytocin and vasopressin in the modulation of human neur

42 n to determine how intranasally administered oxytocin and vasopressin modulated neural activity when

43 motion processing; however, the influence of oxytocin and vasopressin on neural activity elicited dur

44 lective antagonists to determine the role of oxytocin and vasopressin V(1a) receptors.

45 strategies have focused on the neuropeptides oxytocin and vasopressin(4-6), which regulate aspects of

46 nter-individual expression variations of the oxytocin and/or vasopressin receptor genes OXTR and AVPR

47 ow that three neuropeptides (beta-endorphin, oxytocin, and dopamine) play particularly important role

48 reath Powered nasal device, intravenous (IV) oxytocin, and placebo-and investigated the association w

49 tion of RLN3 is RXFP3-mediated inhibition of oxytocin- and arginine-vasopressin-synthesizing paravent

50 l interaction and social reward, mediated by oxytocin; and that in females the dose-response relation

51 Further, high concentrations of endogenous oxytocin are in regions that overlap with projection fie

52 ingle measurements of salivary and plasmatic oxytocin are used as indicators of the physiology of the

53 re unknown and critical to study to consider oxytocin as a neurohormonal weight loss treatment.

54 Oxytocin at 0.1 mg/kg, which did not alter activity and

55 all, these data indicate that development of oxytocin-based therapies may be a promising treatment ap

56 nally, we report that SLO2.1 is inhibited by oxytocin binding to the oxytocin receptor.

57 Oxytocin blocked the facilitatory effects of acute alcoh

58 emerged, showing that, at the spinal level, oxytocin blocks pain transmission.

59 of the oxytocin system, and whether salivary oxytocin can accurately index its plasmatic concentratio

60 These data indicate that oxytocin can modulate hippocampal function in CHR-P indi

61 In this regard, at the cortical level, oxytocin can modulate the GABAergic transmission; conseq

62 acebo is consistent with the hypothesis that oxytocin can travel to the brain via a nose-to-brain rou

63 simple model of the osmoresponsive inputs to oxytocin cells achieves a strikingly close match to dive

64 del of the spiking and secretion activity of oxytocin cells against published evidence of changes in

65 hat relate either the electrical activity of oxytocin cells or the secretion of oxytocin to experimen

66 reduced pupil diameter after 8IU intranasal oxytocin compared to placebo, but no significant differe

67 ce of changes in spiking activity and plasma oxytocin concentration in response to different osmotic

68 n the use of single measurements of baseline oxytocin concentrations in saliva and plasma as valid tr

69 predicts cerebrospinal fluid, but not blood, oxytocin concentrations up to five years after behaviour

70 fferences in face recognition and endogenous oxytocin concentrations.

71 The current results revealed that oxytocin consistently and significantly decreased the in

72 cial behavior, the hypothalamic neuropeptide oxytocin contributes to metabolic control by suppressing

73 dependent but not in dependent rats, whereas oxytocin decreased the amplitude of spontaneous GABAergi

74 l recordings from CeA neurons indicated that oxytocin decreases evoked GABA transmission in nondepend

75 Thus, oxytocin decreases the excitatory/inhibitory (E/I) ratio

76 Intranasal oxytocin delivery fully replicated these effects.

77 g and leads to a metaplastic upregulation of oxytocin-dependent long-term depression.

78 Herein, a series of oxytocin derivatives were engineered through conjugation

79 diagnostic microfluidic platform devised for oxytocin determination in both synthetic serum samples a

80 Here, we report that the neuromodulator oxytocin differentially shapes spontaneous activity patt

81 ive mental health and parenting, focusing on oxytocin-dopamine interactions.

82 ress oxytocin receptors and are activated by oxytocin during male sexual behavior.

83 ntagonist (BRL 44408) partially reversed the oxytocin effect, a descending noradrenergic antinocicept

84 ntral mechanism that may result from altered oxytocin effects on CeA GABA transmission in alcohol dep

85 finish by assessing how three key hormones- oxytocin, estrogen, and progesterone-modulate and integr

86 avior have mainly focused on the vasopressin-oxytocin family.

87 n single-dose and repeated administration of oxytocin for autism spectrum disorder have led researche

88 l trials examining the effects of intranasal oxytocin for improving social and behavioral function in

89 measured baseline plasmatic and/or salivary oxytocin from two independent datasets.

90 social environment (G(s)) interacts with the oxytocin genotype of the focal individual (G(i)) in the

91 ly elevated from baseline to endpoint in the oxytocin-group compared with the placebo-group (effect s

92 Although pharmacological administration of oxytocin has implicated this neuropeptide in face percep

93 e, the brain tissue penetrance of intranasal oxytocin has not been demonstrated.

94 s indicates that a single dose of intranasal oxytocin has positive effects on social function and mar

95 We also discuss how the neuropeptide oxytocin impacts these circuits and their downstream eff

96 rTPJ activity and accuracy, indicating that oxytocin improved rTPJ activity in schizophrenia predict

97 ed (exogenously administered) and endogenous oxytocin in 12 brain regions two hours after oxytocin ad

98 r intracerebroventricular injection of 10 nM oxytocin in dependent rats.

99 nisms underlying the anorexigenic effects of oxytocin in humans are unknown and critical to study to

100 modulatory role of the neuropeptide hormone oxytocin in motivating extraordinary levels of in-group

101 fold increase in the oral bioavailability of oxytocin in pigs in the absence of cellular disruption o

102 pport this argument by examining the case of oxytocin in relation to the sentiment of love.

103 The colocalization of FOS and oxytocin in sites that project to the VTA following soci

104 The role of oxytocin in social cognition has attracted tremendous in

105 The presence of the hormone oxytocin in the central amygdala makes a mother rat will

106 results suggested that, in rats, release of oxytocin in the lumbar spinal cord is not limited to con

107 the oxytocin receptor and were activated by oxytocin in V1.

108 Oxytocin increases the salience of both positive and neg

109 icant positive correlation was found between oxytocin induced increases in rTPJ activity and accuracy

110 Oxytocin infusion into BNSTam in stress naive mice incre

111 uman primate study, we administer deuterated oxytocin intranasally and intravenously to rhesus macaqu

112 We also administered exogenous oxytocin intravenously and intranasally in a triple dumm

113 ess at the RAIC level.SIGNIFICANCE STATEMENT Oxytocin is a neuropeptide involved in several functions

114 Salivary oxytocin is a weak surrogate for plasmatic oxytocin.

115 The peptide hormone oxytocin is an established regulator of social function

116 Oxytocin is currently being considered as a novel therap

117 Despite being efficacious, oxytocin is enzymatically unstable and thus considered t

118 after the last PCA training session, because oxytocin is known to modulate the mesolimbic reward syst

119 Labeled oxytocin is quantified after intranasal (not intravenous

120 ion was independent of contractile stimulus (oxytocin, KCl, U46619).

121 Oxytocin knockdown prevented social stress-induced incre

122 No group differences were observed in plasma oxytocin levels.

123 Oxytocin-like peptides have been implicated in the regul

124 -users in both cohorts showed elevated basal oxytocin, lower ACTH, estradiol, progesterone and testos

125 In rodents, both vasopressin and oxytocin magnocellular neurones are osmoresponsive, and

126 into a previously unknown mechanism by which oxytocin may act to modulate myometrial smooth muscle ce

127 , and an inverted U relationship mediated by oxytocin may have a critical role in assigning positive

128 Oxytocin may have promise as a treatment for neuropsychi

129 Oxytocin may mediate pro-social effects by modulating mo

130 The results of the present study reveal that oxytocin may modulate MSMC electrical activity by inhibi

131 ocial-value representations and suggest that oxytocin may promote prosociality by modulating social-v

132 ng experience and mood-regulating effects of oxytocin-MCH are associated with synaptic plasticity in

133 Our data suggest that the oxytocin-MCH pathway can serve as a potential therapeuti

134 We demonstrate that the oxytocin-MCH pathway mediates the effects of sexual acti

135 We identify discrete effects of oxytocin-MCH signaling on depressive behavior and demons

136 In this study, we uncover the role for the oxytocin-MCH signaling pathway in mood regulation.

137 de evidence that developmental regulation of oxytocin-mediated synaptic plasticity (long-term depress

138 we tested in male Wistar rats the effect of oxytocin microinjection into RAIC during an inflammatory

139 Oxytocin microinjection produces a diminution of (1) fli

140 inical trials in ASD children with oxytocin, oxytocin mimetics and additional tentative therapeutics

141 We show that integrating this oxytocin model with a simple model of the osmoresponsive

142 0.3 mg/kg oxytocin modestly reduced activity and caused hypothermi

143 Oxytocin-modulated DA neurons give rise to canonical str

144 salivary oxytocin observed after intranasal oxytocin most likely reflect unabsorbed peptide and shou

145 n-to-treat sample included 107 participants (oxytocin: n = 53; placebo: n = 54).

146 n contrast, only mantellids showed increased oxytocin neuron activity akin to that in nursing mammals

147 Magnocellular vasopressin and oxytocin neurones in the rat hypothalamus project to the

148 A quantitative model of oxytocin neurones that combines a spiking model, a model

149 Magnocellular and parvocellular oxytocin neurons have been proposed to subserve two para

150 erization of magnocellular and parvocellular oxytocin neurons in male mice, validated across anatomic

151 question of whether different populations of oxytocin neurons mediate different effects on behavior.

152 show that a population of extrahypothalamic oxytocin neurons plays a key role in controlling stress-

153 ministration and chemogenetic stimulation of oxytocin neurons render males sensitive to the distress

154 Viral tracing of BNSTmv oxytocin neurons revealed fibers in regions controlling

155 ynthesis in a stress-sensitive population of oxytocin neurons specifically within the medioventral be

156 in parvocellular compared with magnocellular oxytocin neurons.

157 acute slices of the lumbar cord showed that oxytocin-neurophysin-immunoreactivity was detected in la

158 ng polymer, molecular cavities selective for oxytocin nonapeptide, an autism biomarker, were designed

159 The increases in salivary oxytocin observed after intranasal oxytocin most likely

160 and biomarker changes in the glucocorticoid, oxytocin, oestrogen and immune systems, as key biologica

161 ist did not reverse the effect of intranasal oxytocin on alcohol drinking.

162 ly verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and

163 The effects of oxytocin on food intake and body weight reduction have b

164 ent study examined the effects of intranasal oxytocin on hippocampal blood flow in CHR-P individuals.

165 The effects of oxytocin on left hippocampal blood flow were examined in

166 Further characterization of the effects of oxytocin on neural circuits in the hypothalamus is neede

167 rence between 8IU intranasal oxytocin and IV oxytocin on right amygdala activity and pupil diameter,

168 -scale studies have described the effects of oxytocin on social deficits in autism spectrum disorder

169 e, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probabi

170 tranasal oxytocin and either 24IU intranasal oxytocin or IV oxytocin treatment conditions.

171 s, intracerebroventricular administration of oxytocin or the oxytocin receptor agonist PF-06655075, w

172 in social reward, and more specifically, how oxytocin (OT) acts in the mesolimbic dopamine system (MD

173 behaviors in infancy and preschool, assayed oxytocin (OT) and vasopressin (AVP), and measured copare

174 Oxytocin (OT) has been implicated in mediating natural r

175 Low plasma levels of oxytocin (OT) have also been found in ASD patients; rece

176 reterm labour due to the significant role of oxytocin (OT) in the onset of both term and preterm labo

177 Oxytocin (OT) is a critical molecule for social recognit

178 Oxytocin (OT) is a great facilitator of social life but,

179 Oxytocin (OT) is critical for the expression of social b

180 Although the neuropeptide oxytocin (OT) is thought to regulate prosocial behavior

181 Oxytocin (OT) is widely known for promoting social inter

182 ning human research suggest that the hormone oxytocin (OT) may be important for metabolic regulation.

183 How estrogen withdrawal affects oxytocin (OT) neurocircuitry has not been examined.

184 ways mediate the effects of peptides such as oxytocin (OT) on brain physiology when delivered intrana

185 The neurohypophyseal hormone oxytocin (OT) regulates biologic functions in both perip

186 esponses.SIGNIFICANCE STATEMENT Although the oxytocin (OT) system is well known to regulate a diverse

187 efficacy and reliability of using intranasal oxytocin (OT) to clinically enhance social functions rem

188 Recent interest has focused on oxytocin (OT), a neurotransmitter that promotes social p

189 Numerous studies have demonstrated that oxytocin (OT), a peptide hormone, plays an important rol

190 - and amphetamine-related transcript (CART), oxytocin (OX), corticotrophin releasing hormone (CRH) an

191 (n = 33 total), and quantified their AVP and oxytocin (OXT) concentrations.

192 The peptide hormone oxytocin (OXT) exhibits anxiolytic-like properties in an

193 We focused on a prominent neuropeptide, oxytocin (OXT) in the zebrafish as an in vivo model to v

194 neuromodulators such as the peptide hormone oxytocin (OXT) influence the chemosensory communication

195 Oxytocin (OXT) is a nonapeptide that exerts anxiolytic e

196 Oxytocin (OXT) is an important neuromodulator of social

197 The neuropeptide oxytocin (OXT) mediates its actions, including anxiolysi

198 h, we describe a novel role for hypothalamic oxytocin (OXT) neurons in the processing of noxious stim

199 Although oxytocin (OXT) plays an important role in secure attachm

200 Clinical trials using intranasal oxytocin (OXT) show promise to improve feeding deficits

201 Recently, oxytocin (OXT) showed potential as the first anti-ASD dr

202 rol discrete aspects of energy balance (e.g. oxytocin (OXT), neuronal nitric oxide synthase 1 (NOS1),

203 future clinical trials in ASD children with oxytocin, oxytocin mimetics and additional tentative the

204 g of the parvocellular but not magnocellular oxytocin pathway is required for autism-relevant social

205 hese results provide the first evidence that oxytocin-pathway-specific pathogenic mechanisms account

206 The pituitary neuropeptide oxytocin promotes social behavior, and is a potential ad

207 We found that oxytocin provokes the release of serotonin, which in tur

208 is known about how intranasally administered oxytocin reaches the brain and modulates social behavior

209 was shown to be a potent full agonist at the oxytocin receptor (OTR) in vitro with good selectivity a

210 The oxytocin receptor (OTR) plays critical roles in social b

211 fferences in salivary DNA methylation of the oxytocin receptor (OXTR) between CM and Non-CM groups of

212 e analogous to the optogenetic excitation of oxytocin receptor (OXTR) expressing neurons in the PFC t

213 The OXT/oxytocin receptor (OXTR) system, through the lateral sep

214 (at RAIC) of the following: (1) L-368899 (an oxytocin receptor [OTR] antagonist) or by (2) bicucullin

215 entricular administration of oxytocin or the oxytocin receptor agonist PF-06655075, which does not cr

216 The effects of oxytocin, selective oxytocin receptor agonists, antagonists, and vehicle inj

217 positive (SST(+)) interneurons expressed the oxytocin receptor and were activated by oxytocin in V1.

218 Administration of a peripherally restricted oxytocin receptor antagonist did not reverse the effect

219 Intrathecal injection of oxytocin receptor antagonist not only attenuates ejacula

220 Oxytocin receptor antagonists (OTR-A) have been develope

221 tion of glutamatergic neurotransmission, and oxytocin receptor expression in both suicide and depress

222 hesis is based primarily on manipulations of oxytocin receptor function, leaving open the question of

223 Several common alleles in the oxytocin receptor gene (OXTR) are associated with altere

224 n of the neurons in the PFC that express the oxytocin receptor gene (Oxtr) impairs the ability to dis

225 Epigenetic modification to the oxytocin receptor gene (OXTR) in ASD could be an informa

226 le mice with Cre-recombinase directed to the oxytocin receptor gene (Oxtr), we revealed that oxytocin

227 studies have reported interaction effects of oxytocin receptor genotype (rs53576) and environmental f

228 Here, we used a zebrafish oxytocin receptor knockout line to investigate how the g

229 or, human vasopressin 1b receptor, and human oxytocin receptor), and pharmacokinetic profiles in rode

230 t glutamate-releasing ARC neurons expressing oxytocin receptor, unlike ARC(POMC) neurons, rapidly cau

231 ntral tegmental area of ASD mice, but not in oxytocin receptor-deficient mice.

232 al agranular insular cortex on GABAergic and oxytocin receptor-expressing neurons.

233 s ability to enter the brain and bind to the oxytocin receptor.

234 O2.1 is inhibited by oxytocin binding to the oxytocin receptor.

235 We found that oxytocin-receptor-expressing neurons in the parabrachial

236 ter ovary cells expressing marmoset or human oxytocin receptors (mOTRs or hOTRs, respectively) were u

237 In the nucleus accumbens (NAc) activation of oxytocin receptors (OTR) promotes social approach (time

238 r of social behaviors via activation of both oxytocin receptors (OXTR) and vasopressin (AVP) 1a recep

239 Social cognition is facilitated by oxytocin receptors (OXTR) in the hippocampus, a brain re

240 ence of long-term SRM.SIGNIFICANCE STATEMENT Oxytocin receptors (OXTRs) are abundantly expressed in h

241 tocin receptor gene (Oxtr), we revealed that oxytocin receptors (OXTRs) are expressed on glutamatergi

242 Activation of oxytocin receptors (OXTRs) facilitates neuronal excitabi

243 Here, we show that SEG/GRP neurons express oxytocin receptors and are activated by oxytocin during

244 this critical period requires activation of oxytocin receptors in the nucleus accumbens, and is reca

245 more rewarding than males and activation of oxytocin receptors in the VTA is critical for social rew

246 ion-a localized volume transmission-to reach oxytocin receptors on GRP neurons and facilitate male se

247 re, we investigate the sex-dependent role of oxytocin receptors within the ventral tegmental area (VT

248 Among the secondary endpoints, oxytocin reduced ADOS repetitive behavior (2.0 to 1.5; P

249 Since oxytocin reduced the primary endpoint, Autism Diagnostic

250 Oxytocin, relative to placebo, significantly increased a

251 udied how the gain of osmotically stimulated oxytocin release changes in the presence of a hypovolaem

252 vioral effect, suggesting a tonic endogenous oxytocin release during inflammatory nociceptive input.

253 to inform our understanding of nose-to-brain oxytocin routes and possible dose-response relationships

254 cing of V1 SST(+) interneurons fully blocked oxytocin's effect on inhibition in vitro as well its eff

255 t model of alcohol dependence to investigate oxytocin's effects on dependence-induced alcohol drinkin

256 en, although this large-scale trial suggests oxytocin's possibility to treat ASD repetitive behavior.

257 ressin secretion promotes antidiuresis while oxytocin secretion promotes natriuresis.

258 Specifically, we found that oxytocin seems to be mostly driven by changes in emotion

259 The effects of oxytocin, selective oxytocin receptor agonists, antagoni

260 e use a variety of approaches to discern how oxytocin-sensitive neurons in the PFC exert descending c

261 These results suggest that an oxytocin-sensitive PFC to BLA circuit is required for so

262 Furthermore, blocking oxytocin signaling in the CeL prevented the suppression

263 social function in mammals, and dysregulated oxytocin signaling is implicated in autism spectrum diso

264 Neuroadaptations in endogenous oxytocin signaling may provide a mechanism to further ou

265 ysis revealed sex-specific modulation of the oxytocin signaling pathway and common pathway of fibrin

266 e results suggest that any modulation of the oxytocin signaling pathway induced by OXTR hypermethylat

267 tation of conspecific cues in the absence of oxytocin signaling.

268 resets the translation of mRNA and restores oxytocin signalling and social novelty responses.

269 adhesion molecule Nlgn3 results in impaired oxytocin signalling in dopaminergic neurons and in alter

270 needed to establish the utility of targeting oxytocin signalling in obesity.

271 ese results provide converging evidence that oxytocin specifically and selectively blocks the enhance

272 In vivo, oxytocin strongly decreased the frequency and pairwise c

273 Here we inhibited oxytocin synthesis in a stress-sensitive population of o

274 valid trait markers of the physiology of the oxytocin system in humans.

275 n the SEG neurons and the hypothalamo-spinal oxytocin system in rats.

276 These data indicate that the oxytocin system is involved in social-separation respons

277 valid trait markers of the physiology of the oxytocin system, and whether salivary oxytocin can accur

278 uired cortical activity and the hypothalamic oxytocin system.

279 used as indicators of the physiology of the oxytocin system.

280 inhibitory neurons similarly, whereas in V1, oxytocin targets only inhibitory neurons.

281 bens, and is recapitulated by stimulation of oxytocin terminals in the nucleus accumbens.

282 logues of mammalian arginine vasopressin and oxytocin that are broadly implicated in neural mechanism

283 tivity of oxytocin cells or the secretion of oxytocin to experimentally induced changes in plasma osm

284 bypasses the blood-brain barrier, delivering oxytocin to specific brain regions, such as the striatum

285 ntranasally administered the peptide hormone oxytocin to the same 57 individuals in a randomized tria

286 This highlights the therapeutic potential of oxytocin to treat social behavioral deficits seen in psy

287 s, we cannot recommend continuous intranasal oxytocin treatment alone at the current dose and duratio

288 in and either 24IU intranasal oxytocin or IV oxytocin treatment conditions.

289 ted improvement in social symptoms following oxytocin treatment in autism spectrum disorders (ASD), w

290 Compared with placebo, oxytocin treatment yielded enhanced RHI responses, again

291 rther development of an optimized regimen of oxytocin treatment.

292 -including two different doses of intranasal oxytocin using a novel Breath Powered nasal device, intr

293 investigated to gain novel insights into the oxytocin/vasopressin peptide-receptor interaction, which

294 he SLO2.1 channel is negatively regulated by oxytocin via Galphaq-protein-coupled receptor activation

295 nce imaging study, a single dose of 40 IU of oxytocin was administered via nasal spray to male indivi

296 Relative to placebo, administration of oxytocin was associated with increased hippocampal blood

297 CI, -0.46 to 0.31; P = .69); however, plasma oxytocin was only elevated from baseline to endpoint in

298 coupling and a model of plasma clearance of oxytocin was tested.

299 on of 2,930 formulations of the peptide drug oxytocin, we discovered an absorption enhancer that resu

300 Finally, in Experiment 3, levels of plasma oxytocin were measured in STs and GTs seven days after t